Recent Prostate Cancer News

Xtandi® A New Standard Treatment for Men with Non-Metastatic Castration-Resistant Prostate Cancer? (February 22, 2018)

CancerConnect News:  Results from the Phase 3 PROSPER clinical trial in patients with non-metastatic Castration-Resistant Prostate Cancer (CRPC) were released this week at the 2018 Genitourinary Cancers... Continue Reading

Erleada is The First Treatment for Non-metastatic Castration-resistant Prostate Cancer (February 19, 2018)

CancerConnect News:  Men who are being treated with androgen deprivation therapy (ADT) and see their prostate specific antigen (PSA) levels begin to increase have a new treatment option. The U.S. Food... Continue Reading

Myriad’s myRisk® Hereditary Cancer Test Finds More Than 12 Percent of Men with Prostate Cancer Carry an Inherited Genetic Mutation (February 14, 2018)

Myriad Genetics a leader in molecular diagnostics and personalized medicine, announced today that results from a large 1,162 patient study will be featured during the poster presentation at the 2018 Genitourinary... Continue Reading

Two Advances in Prostate Cancers You Might Not Know About (September 8, 2017)

Prostate cancer isn’t just about men, and it may be inherited. A recent study led by Peter Nelson, MD (Fred Hutchinson Cancer Research Center) has shown that 12% of advanced prostate cancers may be caused... Continue Reading

Is Lynparza a Precision Cancer Medicine for Prostate Cancer? (July 12, 2017)

Scientists have developed a new three-in-one blood test that has the potential to turn Lynparza (olaparib) into a precision medicine for prostate cancer. Lynparza is a PARP inhibitor, a newer precision... Continue Reading

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival (June 7, 2017)

Adding Zytiga (abiraterone acetate) plus prednisone to standard hormonal therapy for men with newly diagnosed, metastatic prostate cancer lowers the chance of death by 38%, and more than doubled the median... Continue Reading

Unique Gene Signature Predicts Potentially Lethal Prostate Cancers (February 23, 2017)

Standard therapy for prostate cancer, the third-leading cause of cancer-related deaths in American men, is based on blocking androgens, the male sex hormones. However, for some men, prostate cancer recurs... Continue Reading

Different Treatment Options Appear Equally Effective in Early Prostate Cancer (October 3, 2016)

Among men with early prostate cancer that is detected through prostate-specific antigen (PSA) testing, treatment with either surgery, radiation therapy, or monitoring until progression all appear to provide... Continue Reading

Midlife PSA Levels Correlate to Risk of Future Lethal Prostate Cancer (August 15, 2016)

A baseline prostate-specific antigen (PSA) level among men at midlife appears to be highly correlated with the risk of developing lethal prostate cancer within their lifetimes. These results were recently... Continue Reading

New Tool Helps Men Evaluate Watchful Waiting in Early Stage Prostate Cancer (August 10, 2016)

Over 90 percent of prostate cancers are detected at a curable stage, with men more likely to die of other diseases than from this cancer. Although patients with localized, low-risk prostate cancer have... Continue Reading

Next Page »